Cytek Biosciences Inc (NASDAQ:CTKB) — Market Cap & Net Worth
Market Cap & Net Worth: Cytek Biosciences Inc (CTKB)
Cytek Biosciences Inc (NASDAQ:CTKB) has a market capitalization of $544.98 Million ($544.98 Million) as of August 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11599 globally and #2951 in its home market, demonstrating a -7.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytek Biosciences Inc's stock price $4.22 by its total outstanding shares 129142587 (129.14 Million). See capital reinvestment ratio of Cytek Biosciences Inc to understand how much of operating cash flow is reinvested back into capital assets.
Cytek Biosciences Inc Market Cap History: 2021 to 2026
Cytek Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $2.11 Billion to $544.98 Million (-25.69% CAGR).
Index Memberships
Cytek Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.02% | #316 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1160 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.60 Trillion | 0.03% | #543 of 602 |
Weight: Cytek Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cytek Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytek Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.24x
Cytek Biosciences Inc's market cap is 3.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.11 Billion | $127.95 Million | $3.00 Million | 16.47x | 702.30x |
| 2022 | $1.32 Billion | $164.04 Million | $2.58 Million | 8.04x | 511.86x |
| 2023 | $1.18 Billion | $193.01 Million | -$12.15 Million | 6.10x | N/A |
| 2024 | $838.14 Million | $200.45 Million | -$6.02 Million | 4.18x | N/A |
| 2025 | $652.17 Million | $201.49 Million | -$66.54 Million | 3.24x | N/A |
Competitor Companies of CTKB by Market Capitalization
Companies near Cytek Biosciences Inc in the global market cap rankings as of August 2, 2026.
Key companies related to Cytek Biosciences Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $183.80 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #189 globally with a market cap of $124.64 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #238 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $183.80 Billion | $105.70 |
| #189 | Stryker Corporation | NYSE:SYK | $124.64 Billion | $325.70 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #238 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $85.39 |
Cytek Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Cytek Biosciences Inc's market cap moved from $2.11 Billion to $ 544.98 Million, with a yearly change of -25.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $544.98 Million | -16.44% |
| 2025 | $652.17 Million | -22.19% |
| 2024 | $838.14 Million | -28.84% |
| 2023 | $1.18 Billion | -10.68% |
| 2022 | $1.32 Billion | -37.44% |
| 2021 | $2.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Cytek Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $544.98 Million USD |
| MoneyControl | $544.98 Million USD |
| MarketWatch | $544.98 Million USD |
| marketcap.company | $544.98 Million USD |
| Reuters | $544.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more